Skip to main
OCGN

Ocugen, Inc. (OCGN) Stock Forecast & Price Target

Ocugen, Inc. (OCGN) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ocugen is a company focused on developing innovative gene and cell therapies and vaccines to address unmet medical needs in a variety of diseases, including retinal diseases such as RP and dAMD. The company's robust pipeline, including its modifier gene therapy platform and regenerative medicine cell therapy platform, positions it well for success in the future. Additionally, the company's recent streamlining of financials and positive results from its Phase 2 study for OCU410 demonstrate its potential for growth and expansion in the market, although it does face competition from other biotechnology and pharmaceutical companies in this field.

Bears say

Ocugen is heavily reliant on external funding and partnerships to finance its pipeline and is at risk of dilution to its shareholders. Additionally, while the company has promising data for its potential gene therapy for Stargardt disease, the competition in the biotech industry and the potential for regulatory setbacks pose significant risks for this product and its others in development. The company's lack of current revenue and the need for future financing add to the risk profile.

Ocugen, Inc. (OCGN) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ocugen, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ocugen, Inc. (OCGN) Forecast

Analysts have given Ocugen, Inc. (OCGN) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Ocugen, Inc. (OCGN) has a Strong Buy consensus rating as of Sep 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ocugen, Inc. (OCGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.